Genentech Avastin Launch Could Be Slowed By Final Packaging Specifications
This article was originally published in The Pink Sheet Daily
The company is understood to be in talks with FDA over the optimal dose for Avastin. A delay would allow Bristol's Erbitux to enjoy at least two months on the market before facing a biologic competitor.
You may also be interested in...
Genentech and FDA are in negotiations over final labeling and Phase IV commitments.
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.